Stock ENLV ENLIVEX THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Enlivex Therapeutics Ltd. Share Price

Equities

ENLV

IL0011319527

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 22/06/2024 am IST 		5-day change 1st Jan Change
1.36 USD +2.79% Intraday chart for Enlivex Therapeutics Ltd. -6.85% -49.63%
17/06 Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis CI
14/06 Enlivex Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Financials

Sales 2024 * - Sales 2025 * - Capitalization 28.39M 2.37B
Net income 2024 * -17M -1.42B Net income 2025 * -14M -1.17B EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-1.68 x
P/E ratio 2025 *
-2.31 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.17%
More Fundamentals * Assessed data

Chart Enlivex Therapeutics Ltd.

Dynamic Chart

Latest news about Enlivex Therapeutics Ltd.

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis CI
Enlivex Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
HC Wainwright Adjusts Price Target on Enlivex Therapeutics to $6 From $7, Maintains Buy Rating MT
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis CI
Enlivex Therapeutics to Launch Registered Direct Offering; Shares Fall MT
Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial MT
Enlivex Therapeutics Ltd. Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra? in Patients with Knee Osteoarthritis CI
Enlivex Therapeutics Receives Approval to Expand Trial of Allocetra to Treat Knee Osteoarthritis Into Denmark MT
Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis CI
HC Wainwright Adjusts Enlivex Therapeutics Price Target to $7 From $12, Maintains Buy Rating MT
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care MT
Enlivex Therapeutics Shares Fall After Topline Data from Sepsis Treatment Study MT
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra? in Patients with Sepsis CI
Tranche Update on Enlivex Therapeutics Ltd.'s Equity Buyback Plan announced on September 18, 2023. CI
More news

Analyst Recommendations on Enlivex Therapeutics Ltd.

HC Wainwright Adjusts Price Target on Enlivex Therapeutics to $6 From $7, Maintains Buy Rating MT
HC Wainwright Adjusts Enlivex Therapeutics Price Target to $7 From $12, Maintains Buy Rating MT
HC Wainwright Cuts Enlivex Therapeutics Price Target to $12 From $15, Maintains Buy Rating MT
HC Wainwright Adjusts Enlivex Therapeutics' Price Target to $15 from $33, Keeps Buy Rating MT
More recommendations

Press releases Enlivex Therapeutics Ltd.

Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 GL
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 AQ
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis GL
ENLIVEX THERAPEUTICS : CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2024 AND 2023 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2024 AND 2023 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Form 6 K PU
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis GL
More press releases

Quotes and Performance

1 day+2.79%
1 week-6.85%
1 month-5.56%
3 months-63.04%
6 months-53.42%
Current year-49.63%
More quotes

Highs and lows

1 week
1.26
Extreme 1.26
1.66
1 month
1.18
Extreme 1.18
1.66
Current year
1.15
Extreme 1.15
4.59
1 year
1.15
Extreme 1.15
4.59
3 years
1.15
Extreme 1.15
13.95
5 years
1.15
Extreme 1.15
44.90
10 years
1.15
Extreme 1.15
44.90
More quotes

Managers and Directors - Enlivex Therapeutics Ltd.

Managers TitleAgeSince
Oren Hershkovitz CEO
 Chief Executive Officer 47 16/19/16
Dror Mevorach FOU
 Founder 68 01/09/01
Shachar Shlosberger DFI
 Director of Finance/CFO 47 01/16/01
Members of the board TitleAgeSince
Shai Novik CHM
 Chairman 58 01/14/01
Avri Havron BRD
 Director/Board Member 76 01/14/01
Brian Schwartz BRD
 Director/Board Member 52 01/20/01
More insiders

Quotes

Date Price Change Volume
21/24/21 1.36 +2.79% 32,687
20/24/20 1.323 +2.57% 75,972
18/24/18 1.29 -7.19% 117,127
17/24/17 1.39 -4.79% 363,247
14/24/14 1.46 -1.28% 47,502

Delayed Quote Nasdaq, June 22, 2024 at 01:30 am IST

More quotes

Company Profile

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Sector
Biotechnology & Medical Research
Calendar
26/06/2024 - Business Update Call
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.36 USD
Average target price
6 USD
Spread / Average Target
+341.18%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ENLIVEX THERAPEUTICS LTD. Stock Enlivex Therapeutics Ltd.
-49.63% 28.39M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.19% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.91% 114B
BIONTECH SE Stock BioNTech SE
-19.80% 20.43B
GENMAB A/S Stock Genmab A/S
-16.19% 16.55B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.45% 16.45B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.35% 15.59B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+66.67% 15.19B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.13% 13.54B
INSMED INCORPORATED Stock Insmed Incorporated
+119.39% 10.96B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ENLV Stock